Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ãëàçíûå áîëåçíè

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 28.09.2008, 19:52
_Mary _Mary âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.06.2008
Ãîðîä: Ìîñêîâñêàÿ îáëàñòü
Ñîîáùåíèé: 29
Ñêàçàë(à) ñïàñèáî: 11
_Mary *
Âèðóñíûé êîíúþíêòèâèò

Çäðàâñòâóéòå!
Ðåáåíîê áîëååò êàæäóþ âåñíó è îñåíü âìåñòå ñî ìíîé àäåíîâèðóñíûì êîíúþíêòèâèòîì (òàêîé äèàãíîç ñòàâèò âðà÷- îôòàëüìîëîã). Ïðè ýòîì ó ìåíÿ ñ ðåáåíêîì òàêæå åñòü íåáîëüøîé íàñìîðê, êàøåëü. ß äóìàþ, ÷òî ïðèíîñèò âèðóñ èç ñàäà. Ñûíó 4,5 ãîäà, ðàíüøå áîëåë î÷åíü ÷àñòî ÎÐÂÈ â ÿñëÿõ. Ñåé÷àñ â îñíîâíîì îäèí êîíúþíêòèâèò íîñèò. Áûâàåò áîëåçíü ðàñòÿãèâàåòñÿ íà ìåñÿö- ïîëòîðà. Õîòåëà áû ñïðîñèòü ó âàñ, óâàæàåìûå âðà÷è:
1. Ñóùåñòâóåò ëè êàêàÿ- íèáóäü ïðîôèëàêòèêà ïðîòèâ ýòîãî âèðóñà?
2. Ïî÷åìó âèðóñ â ãëàçàõ íå ïðîõîäèò ñàì ïî ñåáå è îáÿçàòåëüíî êàæäûé ðàç ìû êàïàåì îôòàëüìîôåðîí, àíòèáèîòèêè, òàê êàê ÷àñòî "êðàñíûå ãëàçà" ñî÷åòàþòñÿ ñ ãíîåì. Ìíå ýòî íå ïîíÿòíî, ïîòîìó ÷òî ëþáîå ÎÐÂÈ ó ÷åëîâåêà ïðîõîäèò ñàìî ïî ñåáå çà íåñêîëüêî äíåé, à òóò âñå ïî- äðóãîìó.
3. Âûðàáàòûâàåòñÿ ëè êàêîé- íèáóäü èììóíèòåò ïîñëå ïåðåíåñåííîãî êîíúþíêòèâèòà? Åñòü ëè íàäåæäà, ÷òî ýòî êîãäà- íèáóäü ïðåêðàòèòñÿ?

Íà äàííûé ìîìåíò ðåáåíîê çäîðîâ. Ïðîêàïàëè îôòàëüìîôåðîí 5 äíåé ïî 8 ðàç â äåíü è 7 äíåé ëåâîìèöèòèí ïî 6 ðàç â äåíü. À ó ìåíÿ òàê è íå ïðîøåë, õîòÿ ÿ êàïàëà îôòàëüìîôåðîí 10 äíåé (íà ñåãîäíåøíèé äåíü) è ëåâîìèöåíòèí. .  ëåâîì ãëàçó â óãëó ãëàçà êðàñíûå ñîñóäû è îùóùåíèå ñóõîñòè ãëàçà. Ãíîÿ íåò, ñëèçè òîæå. Õîäèëà êî âðà÷ó. Ïðîïèñàëè ïîëóäàí âìåñòå ñ äåêñàìåòàçîíîì (ïî- ìîåìó îäèí ïðåïàðàò èñêëþ÷àåò äðóãîé, ñóäÿ ïî èíñòðóêöèè).Ïðè îñìîòðå âðà÷ ñêàçàëà, ÷òî â ãëàçàõ åñòü òî÷å÷íûå èíôèëüòðàòû, ÷åì ðàññòðîèëà ìåíÿ âêîíåö. ×òî ýòî çà èíôèëüòðàòû è î ÷åì îíè ãîâîðÿò? Ïîëóäàí ïîïðîáîâàëà, íî îí ó ìåíÿ, ïîõîæå âûçûâàåò àëëåðãèþ (÷óâñòâî èíîðîäíîãî òåëà â ãëàçó è êàê òî ñòàëî õóæå). Ïðîäîëæàþ êàïàòü îôòàëüìîôåðîí 8-9 ðàç â äåíü è ëåâîìèöèòèí 6 ðàç â äåíü. Äåêñàìåòàçîíà áîþñü: â ïðåäûäóùèé ðàç òîëüêî ðàñòÿíóë âðåìÿ áîëåçíè äî 2 ìåñÿöåâ, à â èòîãå ÿ âñå ðàâíî âûëå÷èëàñü îôòàëüìîôåðîíîì.

ß ñîâñåì óæå çàïóòàëàñü ñ ýòèì êîíúíêòèâèòîì. Áóäó î÷åíü ïðèçíàòåëüíà, åñëè ïðîÿñíèòå äëÿ ìåíÿ ñèòóàöèþ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 29.09.2008, 18:17
Darina38 Darina38 âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 27.11.2007
Ãîðîä: Tashkent
Ñîîáùåíèé: 3,486
Ïîáëàãîäàðèëè 1,017 ðàç(à) çà 984 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
Darina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå. Èíôèëüòðàòû íà ðîãîâèöå (òî÷å÷íûå èëè ìîíåòîâèäíûå), ê ñîæàëåíèþ, õàðàêòåðíû äëÿ àäåíîâèðóñíîãî êåðàòîêîíúþíêòèâèòà. Ëå÷åíèå àäåíîâèðóñíîãî êîíúþíêòèâèòà îôòàëüìîôåðîíîì è ëåâîìèöåòèíîì ìîæíî ñ÷èòàòü àäåêâàòíûì. ×òî äåëàòü ñ ÷àñòûìè ÎÐÂÈ (âåäü, ñóäÿ ïî âàøèì ñëîâàì - ýòî ïåðâîïðè÷èíà êîíúþíêòèâèòà) Âàì ëó÷øå ïîèíòåðåñîâàòüñÿ ó òåðàïåâòîâ è èíôåêöèîíèñòîâ (ñîçäàéòå òàì òåìó ñ âîïðîñîì î âîçìîæíûõ ïóòÿõ ïðîôèëàêòèêè ÎÐÂÈ).
Ñ óâàæåíèåì, Äàðèíà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 29.09.2008, 18:25
_Mary _Mary âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.06.2008
Ãîðîä: Ìîñêîâñêàÿ îáëàñòü
Ñîîáùåíèé: 29
Ñêàçàë(à) ñïàñèáî: 11
_Mary *
Ñïàñèáî çà îòâåò!
À ñêîëüêî ïðèìåðíî ïî âðåìåíè íóæíî ëå÷èòü îôòàëüìîôåðîíîì àäåíîâèðóñ, ÷òîáû óæ òî÷íî áûòü óâåðåííîé, ÷òî âèðóñà â ãëàçàõ íåò? 10-14 äíåé äîñòàòî÷íî?
Ïî ïîâîäó èíôèëüòðàòîâ: ðàññàñûâàþòñÿ îíè ñàìè èëè ìîãóò îñòàâëÿòü êàêèå òî íåîáðàòèìûå èçìåíåíèÿ íà ðîãîâèöå? Â áóäóùåì õîòåëà áû ñäåëàòü ËÀÑÈÊ ñåáå. Áîþñü, ÷òî ýòîò àäåíîâèðóñ èëè åãî ïîñëåäñòâèÿ ìîãóò ïîìåøàòü ìíå
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 29.09.2008, 18:43
Darina38 Darina38 âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 27.11.2007
Ãîðîä: Tashkent
Ñîîáùåíèé: 3,486
Ïîáëàãîäàðèëè 1,017 ðàç(à) çà 984 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
Darina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âðåìÿ ëå÷åíèÿ èíäèâèäóàëüíî. Èíîãäà äîñòàòî÷íî è 5 äíåé, à èíîãäà íóæíî áîëüøå. Âñå çàâèñèò îò êëèíèêè, à îíà îïðåäåëÿåòñÿ Âàøèìè ñóáúåêòèâíûìè îùóùåíèÿìè è î÷íûì îñìîòðîì îôòàëüìîëîãà. Ñ èíôèëüòðàòàìè òîæå èíäèâèäóàëüíî - ÷àùå ðàññàñûâàþòñÿ, íî èíîãäà, åñëè ðàñïîëàãàþòñÿ ãëóáæå ýïèòåëèÿ ðîãîâèöû - ìîãóò è îñòàòüñÿ â âèäå íåæíûõ ïîìóòíåíèé (íà îñòðîòó çðåèÿ îáû÷íî ñèëüíî íå âëèÿþò). Íàñ÷åò ËÀÑÈÊ - òîæå èíäèâèäóàëüíî. Íî ïîêà íå íàñòóïèò äëèòåëüíûé ïåðèîä ðåìèññèè î ëàçåðíîé êîððåêöèè äóìàòü ðàíî.
Ñ óâàæåíèåì, Äàðèíà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 29.09.2008, 19:44
Àâàòàð äëÿ Morphey
Morphey Morphey âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 07.07.2007
Ãîðîä: Lisbon
Ñîîáùåíèé: 1,839
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 369 ðàç(à) çà 285 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 8
Morphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Darina38 Ïîñìîòðåòü ñîîáùåíèå
Ëå÷åíèå àäåíîâèðóñíîãî êîíúþíêòèâèòà îôòàëüìîôåðîíîì è ëåâîìèöåòèíîì ìîæíî ñ÷èòàòü àäåêâàòíûì.
ß ïîæàëóé íå ñîãëàøóñü ñ êîëëåãîé. Îôòàëüìîôåðîí... ÷òî ýòî??? Ýòî íå íóæíî. Î ðàçëè÷íûõ *ôåðîíàõ, ïî ìîåìó óæå î÷åíü ìíîãî áûëî íàïèñàíî è ñêàçàíî.

Ëåâîìèöåòèí... íåò åãî â ðåêîìåíäàöèÿõ, ðóêîâîäñòâàõ ïî âåäåíèþ êîíúþêòèâèòîâ.  ñëó÷àå âèðóñíûõ, òåì áîëåå.

Äëÿ âðà÷åé. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

ïðè íîðìàëüíîì ñòå÷åíèè îáñòîÿòåëüñòâ áàêòåðèàëüíûé êîíúþêòèâèò ïðîõîäèò ñàìîñòîÿòåëüíî çà 2 íåäåëè. Ëå÷åíèå è èìåííî áîëåå áûñòðîå âûçäîðîâëåíèå íåîáõîäèìî ñ öåëüþ íåäîïóùåíèÿ çàðàæåíèÿ äðóãèõ/äåòÿì íå ïðîïóñêàòü øêîëó/èõ ðîäèòåëÿì ðàáîòó. Íà ñåãîäíÿøíèé äåíü íåò îäíîçíà÷íîãî ìíåíèÿ, íàçíà÷àòü ëè ÀÁ ñðàçó, èñõîäÿ èç äàííûõ ïîñëåäíèõ èññëåäîâàíèé (òðèàëîâ) áîëåå ñêëîíÿþòñÿ, åñëè è íàçíà÷àòü ÀÁ òî ñ îòñðî÷êîé â íåñêîëüêî äíåé.[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


Ïðè èìåþùèõñÿ ïîêàçàíèÿõ ê íàçíà÷åíèþ àíòèáèîòèêà âûáîð îíîãî îïðåäåëÿåòñÿ ñëåäóþùèìè êðèòåðèÿìè: àäåêâàòíîñòü ïðè íàçíà÷åíèè ÀÁ (íå âñåì ïîäðÿä) è ïðàâèëüíûé âûáîð (ìàêñèìàëüíîå ïîêðûòèå ñïåêòðà áàêòåðèé, îòñóòñòâèå ðåçèñòåíòíûõ øòàììîâ).
Ïðåäñòàâëÿåòñÿ âîçìîæíûì èñïîëüçîâàíèå êàïåëü ôòîðõèíîëîíîâ 2 ïîêîëåíèÿ, îôëîêñàöèíà èëè öèïðîôëîêñàöèíà, èëè áîëåå íîâîãî ïîêîëåíèÿ.
Òàêæå, âûñîêî ýôôåêòèâíû êàïëè ñ àçèòðîìèöèíîì, îäíàêî íå óâåðåí, ÷òî åñòü â Ðîññèè.[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 29.09.2008, 20:26
_Mary _Mary âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.06.2008
Ãîðîä: Ìîñêîâñêàÿ îáëàñòü
Ñîîáùåíèé: 29
Ñêàçàë(à) ñïàñèáî: 11
_Mary *
Öèòàòà:
Ñîîáùåíèå îò Morphey Ïîñìîòðåòü ñîîáùåíèå
ß ïîæàëóé íå ñîãëàøóñü ñ êîëëåãîé. Îôòàëüìîôåðîí... ÷òî ýòî??? Ýòî íå íóæíî. Î ðàçëè÷íûõ *ôåðîíàõ, ïî ìîåìó óæå î÷åíü ìíîãî áûëî íàïèñàíî è ñêàçàíî.
Ñïàñèáî çà îòâåò.
À ÷òî òîãäà íóæíî, åñëè ãëàçà ïðè ýòîì åëå îòêðûâàþòñÿ, ÷åøóòñÿ, òå÷åò ñëèçü, è ÷àùå âñåãî èäåò åùå è ãíîé? Îôòàëüìîôåðîí äåéñòâèòåëüíî î÷åíü ïîìîãàåò, ïðàâäà, âîçìîæíî, òîëüêî ñíèìàåò ñèìïòîìàòèêó.  íåì êðîìå èíòåðôåðîíà ñîäåðæèòñÿ,íàïðèìåð, åùå äèìåäðîë, áîðíàÿ êèñëîòà è ò.ä. Åñëè íå îôòàëüìîôåðîí, òî ÷åì òîãäà õîòÿ áû îáëåã÷èòü ñîñòîÿíèå ãëàç ïðè ýòîì?
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 29.09.2008, 20:49
Àâàòàð äëÿ Morphey
Morphey Morphey âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 07.07.2007
Ãîðîä: Lisbon
Ñîîáùåíèé: 1,839
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 369 ðàç(à) çà 285 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 8
Morphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñîððè, âñå íàïèñàíî âûøå. Òî, ÷òî ïîìîãàåò, èëè Âàì êàæåòñÿ... ýòî äâå áîëüøèå ðàçíèöû. Ïîïðîáóéòå îáû÷íûé ôèçðàñòâîð, âîçìîæíî ýôôåêò áóäåò òîò æå. Î ïîêàçàíèÿõ è ðåæèìå äîçèðîâàíèÿ àíòèáèîòèêîâ, òàêæå íàïèñàíî. Ïðåïàðàò ñ ýòèì ñîñòàâîì, íå äîëæåí íàçíà÷àòüñÿ íè äåòÿì íè âçðîñëûì.

Öèòàòà:
Ñîñòàâ
1 ìë ãëàçíûõ êàïåëü ñîäåðæèò èíòåðôåðîí ÷åëîâå÷åñêèé ðåêîìáèíàíòíûé àëüôà-2b - íå ìåíåå 10000 ÌÅ, äè-ìåäðîë - 0,001 ã, áîðíàÿ êèñëîòà - 0,0031 ã, ïîëèâèíèëïèððîëèäîí - 0,01 ã, ïîëèýòèëåíîêñèä - 0,05 ã, òðèëîí Á - 0,0004 ã, ãèïðîìåëëîçà - 0,003 ã, íàòðèÿ õëîðèä - 0,004 ã, íàòðèÿ àöåòàò - 0,007 ã

Ôàðìàêîëîãè÷åñêîå äåéñòâèå

Èììóíîìîäóëèðóþùåå, ïðîòèâîâèðóñíîå, ïðîòèâîàëëåðãè÷åñêîå, ïðîòèâîâîñïàëèòåëüíîå, ïðîòèâîìèêðîáíîå, ìåñòíîàíåñòåçèðóþùåå, ðåãåíåðèðóþùåå.
Ïîêàçàíèÿ
Àäåíîâèðóñíûå (â ò.÷. ïðè âòîðè÷íîé èíôåêöèè ïðè ïîëëèíîçàõ), ãåìîððàãè÷åñêèå (ýíòåðîâèðóñíûå), ãåðïåòè÷åñêèå êîíúþíêòèâèòû, àäåíîâèðóñíûå, ãåðïåòè÷åñêèå (âåçèêóëåçíûé, òî÷å÷íûé, äðåâîâèäíûé, êàðòîîáðàçíûé) êåðàòèòû, ãåðïåòè÷åñêèé ñòðîìàëüíûé êåðàòèò ñ èçúÿçâëåíèåì ðîãîâèöû è áåç èçúÿçâëåíèÿ, àäåíîâèðóñíûå è ãåðïåòè÷åñêèå êåðàòîêîíúþíêòèâèòû, ãåðïåòè÷åñêèå óâåèòû, ãåðïåòè÷åñêèå êåðàòîóâåèòû (ñ èçúÿçâëåíèÿìè è áåç íèõ).
No comments
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 29.09.2008, 21:16
vadimbondar vadimbondar âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 07.07.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 2,346
Ïîáëàãîäàðèëè 224 ðàç(à) çà 191 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 2
vadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåvadimbondar ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ïðîòèâîâèðóñíûå ïðåïàðàòû ïðè âèðóñíîì êîíúþíêòèâèòå íåýôôåêòèâíû.

Òîëüêî ñèìïòîìàòè÷åñêîå ëå÷åíèå.
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 29.09.2008, 21:46
_Mary _Mary âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 25.06.2008
Ãîðîä: Ìîñêîâñêàÿ îáëàñòü
Ñîîáùåíèé: 29
Ñêàçàë(à) ñïàñèáî: 11
_Mary *
Vadimbondar, à êàê Âû îòíîñèòåñü ê îôòàëüìîôåðîíó? Âû òîæå ñ÷èòàåòå, ÷òî åãî íåëüçÿ ïðèìåíÿòü íè äåòÿì, íè âçðîñëûì?

Öèòàòà:
Ñîîáùåíèå îò vadimbondar Ïîñìîòðåòü ñîîáùåíèå
Àäåíîâèðóñíûé êîíúþíêòèâèò (òàê íàçûâàåòñÿ ýòî çàáîëåâàíèå) ëå÷èòñÿ ïðîòèâîâèðóñíûìè ïðåïàðàòàìè...
Öèòàòà:
Ñîîáùåíèå îò vadimbondar Ïîñìîòðåòü ñîîáùåíèå
ß ñîâåðøåííî èñêðåííå íàïèñàë , ÷òî ëå÷èòü íå íàäî òî , ÷òî ïðîõîäèò ñàìî. Òàêîå áûâàåò ÷àñòî..

Ïî ïîâîäó êîíúþíóòèâèòà.

Èç ïðîòèâîâèðóñíûõ ïðåïàðàòîâ
ðåêîìáèíàòíûå èíòåðôåðîíû

åñòü òàêèå êàïëè ãëàçíûå - îôòàëüìîôåðîí
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 29.09.2008, 21:57
Darina38 Darina38 âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 27.11.2007
Ãîðîä: Tashkent
Ñîîáùåíèé: 3,486
Ïîáëàãîäàðèëè 1,017 ðàç(à) çà 984 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
Darina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûå êîëëåãè. Ðàçðåøèòå ñ Âàìè ïîñïîðèòü íàñ÷åò ëå÷åíèÿ âèðóñíûõ êîíúþíêòèâèòîâ ôèç. ðàñòâîðîì. Ñïîðèòü áóäó ñ ïîìîùüþ ññûëêè.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Âîò òîëüîê âûäåðæêà , ïîëíîñòüþ ìîæåòå îçíàêîìèòüñÿ ïî ññûëêå...
Medications used in the treatment of viral conjunctivitis include the following: topical artificial tears, 4-8 times per day, for 1-3 weeks; topical vasoconstrictor/antihistamine, 4 times per day, for severe itching; topical steroids for pseudomembranes and subepithelial infiltrates; topical antibiotic to prevent bacterial superinfection; topical antiviral agents for HSV infection; and oral acyclovir for VZV infection.
Drug Category: Ocular lubricants
Used for symptomatic relief.
Drug Name Artificial tears (Refresh, Celluvisc, Murine)
Description Act to stabilize and thicken precorneal tear film and prolong tear film breakup time, which occurs with dry eye states.
Adult Dose 1-2 gtt 4-8 times/d; may use more frequently if preservative free
Pediatric Dose Administer as in adults
Contraindications Documented hypersensitivity
Interactions None reported
Pregnancy A - Safe in pregnancy
Precautions Hyperemia, photophobia, stickiness of eyelashes, and ocular discomfort or irritation may occur
Drug Category: Antihistamines
Used to treat severe itching.
Drug Name Levocabastine (Livostin)
Description Potent histamine H1-receptor antagonist; for ophthalmic use.
Adult Dose 1 gtt in each affected eye qid
Pediatric Dose <12 years: Not established
>12 years: Administer as in adults
Contraindications Documented hypersensitivity
Interactions None reported
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Shake well prior to use; not for internal (systemic) use; avoid use of contact lenses while on medication
Drug Category: Corticosteroids
For pseudomembranes and decreased vision and/or glare due to subepithelial infiltrates. Have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.
Drug Name Prednisolone (AK-Pred, Pred Forte)
Description Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. Less potent (eg, prednisolone 0.125%, fluorometholone 0.1%) are usually sufficient to treat subepithelial infiltrates. The steroid must be tapered very slowly, over months.
Adult Dose 1 gtt q1-6h, depending on severity of infection; taper slowly over several d to wk
Pediatric Dose Administer as in adults
Contraindications Documented hypersensitivity; HSV keratitis; acute viral keratitis; VZV; suspected fungal keratitis; mycobacterial infection; glaucoma
Interactions None reported
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions Caution in patients with glaucoma; corticosteroids are associated with increased intraocular pressure and cataract in some patients; they may worsen certain infections, such as from herpes simplex, bacteria, and fungi
Drug Category: Antivirals
Used for the treatment of HSV infection.
Drug Name Trifluridine (Viroptic)
Description Pyrimidine (thymidine) analogue DOC in the United States for topical antiviral therapy for HSV infection. Inhibits viral replication by incorporating into viral DNA in place of thymidine. If no response in 7-14 d, consider other treatments.
Adult Dose 1 gtt into affected eye q2h while awake; not to exceed 9 gtt/d for 10 d, not to exceed 21 d; taper thereafter
Pediatric Dose Administer as is adults
Contraindications Documented hypersensitivity
Interactions None reported
Pregnancy C - Safety for use during pregnancy has not been established.
Precautions All topical antiviral medications currently available for clinical use in the United States are toxic; adverse reactions include discomfort upon instillation and palpebral edema, irritation, and superficial punctate or epithelial keratopathy
Drug Name Acyclovir (Zovirax)
Description Prodrug activated by phosphorylation by virus-specific thymidine kinase that inhibits viral replication.
Adult Dose Herpes zoster ophthalmicus: 800 mg PO 5 times/d for 7-10 d
Recurrent episodes: 400-800 mg PO bid for 7-10 d; initiate treatment immediately upon onset of symptoms of recurrent episodes
Prevention of herpes simplex infections: 400 mg PO bid, can be used to prevent recurrent herpes simplex infections and inflammations
Pediatric Dose 20 mg/kg/dose PO q6h up to a maximum of 800 mg
Contraindications Documented hypersensitivity; caution in renal disease
Interactions Concomitant use of probenecid or zidovudine prolongs half-life and increases CNS toxicity of acyclovir
Pregnancy B - Usually safe but benefits must outweigh the risks.
Precautions Caution in renal failure or when using nephrotoxic drugs
Ñ óâàæåíèåì, Äàðèíà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 29.09.2008, 22:18
Darina38 Darina38 âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 27.11.2007
Ãîðîä: Tashkent
Ñîîáùåíèé: 3,486
Ïîáëàãîäàðèëè 1,017 ðàç(à) çà 984 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
Darina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
 ïðîäîëæåíèå äèñêóññèè âûëîæó åùå äâå ññûëêè, îíè, êîíå÷íî íå ïðî îôòàëüìîôåðîí (òàêîãî ïðåïàðàòà íà Çàïàäå íåò), íî àíòèãèñòàìèíû è àíòèáèîòèêè äëÿ ïðîôèëàêòèêè íàñëîåíèÿ âòîðè÷íîé áàêòåðèàëüíîé èíôåêöèè, è êðîìå òîãî, ñîîáùåíèÿ î ëå÷åíèè ðèáàâèðèíîì è öèäîâèðîì â íèõ ïðèñóòñòâóþò.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Pharyngoconjunctival Fever
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Adenovirusesâûäåðæêà...
Currently, specific therapy for adenovirus infection, other than supportive and symptomatic treatment, remains a matter of debate.
Òàê ÷òî íå ñîâñåì âñå îêîí÷àòåëüíî ÿñíî ñ ýòèì âîïðîñîì. Òåì áîëåå, ÷òî áóäó÷è ïðàêòè÷åñêèì îôòàëüìîëîãîì, ÷àñòî ïðèíèìàþ ïàöèåíòîâ ñ àäåíîâèðóñíûì êîíúþíêòèâèòîì, êîòîðûå äâå íåäåëè äóìàëè, ÷òî âñå ïðîéäåò è òàê (÷àåì ïðîìûâàëè ãëàçà). À ðåçóëüòàò - èíôèëüòðàòû íà ðîãîâèöå è íàñëîåíèå âòîðè÷íîé áàêòåðèàëüíîé èíôåêöèè.
Ñ óâàæåíèåì, Äàðèíà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 29.09.2008, 23:07
Àâàòàð äëÿ Morphey
Morphey Morphey âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 07.07.2007
Ãîðîä: Lisbon
Ñîîáùåíèé: 1,839
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 369 ðàç(à) çà 285 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 8
Morphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Êîëëåãà, äàííûé ðåñóðñ, â ïðèíöèïå íå ïîñëåäíèé èñòî÷íèê, î áîëüøîì êîëè÷åñòâå ëÿïîâ êîòîðîãî, íàïðèìåð, íå ðàç ïèñàëà ßíà, è íå ðàç îáñóæäàëîñü - èñïîëüçîâàòü ìîæíî, íî â êà÷åñòâå îçíàêîìëåíèÿ. Ñêîðåå äëÿ ìëàäøåãî çâåíà, íåñïåöèàëèñòîâ. ß, íàïðèìåð, êàê íåñïåöèàëèñò â îáëàñòè îôòàëüìîëîãèè ìîãó îçíàêîìèòüñÿ ñ ïðèíöèïàìè ëå÷åíèÿ êåðàòîêîíúþêòèâèòîâ, èëè èðèäîöèêëèòîâ, íå áîëåå.

Íî ïîñìîòðèì, ÷òî Âû ïðåäñòàâèëè.
Èç ïåðâîé Âàøåé ññûëêè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
* Because PCF usually is a self-limited disease, treatment is mainly symptomatic, as follows:
* Cold compresses several times per day for 1-2 weeks o Artificial tears 4-8 times per day for 1-3 weeks
* The following drugs may be used but rarely are indicated:
* A topical vasoconstrictor/antihistamine may be instilled 4 times per day for severe itching only, because it may cause a rebounding of symptoms and it has a high incidence of local toxicity and hypersensitivity.
o A topical astringent or antibiotic may be instilled 4 times per day to prevent bacterial superinfection.
o Topical steroids dramatically suppress conjunctival inflammatory signs, relieve symptoms, and are associated with resolution of the corneal subepithelial infiltrates. However, due to their adverse effects, topical steroids should only be used for pseudomembranes or when subepithelial infiltrates severely reduce vision. Subepithelial infiltrates may recur after discontinuing the steroids. Therapy should be maintained for one to a few weeks and then slowly tapered over months. Extreme caution must be taken when giving steroids to any patient with follicular conjunctivitis because it may worsen an underlying herpes simplex viral infection. Furthermore, topical steroids should be avoided during the first 2 weeks of infection during active viral replication.
o Although adenovirus has been found to be sensitive to idoxuridine and trifluorothymidine in vitro, none of the commercially available antivirals have been shown to be effective clinically. On the other hand, topical cidofovir has been shown to be highly effective in the eradication of actively replicating viruses and limiting the time of symptomatology. Further clinical study is warranted to determine the long-term adverse effects of topical cidofovir, including the possibility of epithelial toxicity, secondary corneal infiltrates, and punctal stenosis. Topical cidofovir is also effective clinically against herpes simplex, molluscum contagiosum, and human papilloma virus.
o Topical human fibroblast interferon has been shown to have some success, but it is still an experimental treatment.
o An in vitro study using adenovirus 8 and A549 human epithelial cell cultures demonstrated that povidone-iodine at a concentration of 1:10 (0.8%) is highly effective against free adenovirus, less effective against intracellular adenoviral particles in already infected cells, and not significantly cytotoxic for healthy cells. Thus, povidone-iodine 0.8% may represent a potential option to reduce contagiousness in cases of adenoviral infections.
Èç âòîðîé:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Currently, specific therapy for adenovirus infection, other than supportive and symptomatic treatment, remains a matter of debate.

* Several case reports of successes with ribavirin therapy have been cited for serious adenoviral disease in immunocompromised patients; however, the number of failed treatments that have not been reported remains uncertain.

No available studies adequately address issues such as which syndromes are most likely to respond to treatment, which patients develop limiting hematologic toxicity from ribavirin or nephrotoxicity from cidofovir, or which patients, if any, may benefit from adjunctive therapy with leukocyte transfusions.

Fortunately, most infections are self-limited in the setting of a normal immune response and do not warrant specific therapy.
Îòâåòèòü ñ öèòèðîâàíèåì
  #13  
Ñòàðûé 29.09.2008, 23:17
Àâàòàð äëÿ Morphey
Morphey Morphey âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 07.07.2007
Ãîðîä: Lisbon
Ñîîáùåíèé: 1,839
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 369 ðàç(à) çà 285 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 8
Morphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMorphey ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Èòàê, âñå ïðèâåäåííûå Âàìè ìàòåðèàëû, Äàðèíà, ñâèäåòåëüñòâóþò îá îäíîì - âñå íà ýêñïåðèìåíòàëüíîì óðîâíå. Ðèáàâèðèí è Ñèäîôîâèð ñêîðåå îáëàäàþò áîëåå òÿæêèìè ïîáî÷êàìè, íåæåëè ëå÷åáíûì ýôôåêòîì. Óïîìÿíóòûé èíòåðôåðîí, âî ïåðâûõ îòëè÷àåòñÿ îò "îôòàëüìîôåðîíà" íî è îïÿòü æå íåò èíôîðìàöèè, äîêàçàòåëüñòâ ýôôåêòèâíîñòè.

ß íå äóìàþ, ÷òî ñòàâèòü ýêñïåðèìåíòû íàä ëþäüìè ýòî ýòè÷íî, èëè ïðîñòî õîðîøî.
Âàø êëèíè÷åñêèé îïûò, ðàâíî êàê è ìîé, îòäåëüíî âçÿòûå íå ìîãóò ðàññìàòðèâàòüñÿ â êà÷åñòâå êàêèõ ëèáî äîêàçàòåëüñòâ. Ýòî "ïèööîò" ðàç îáñóæäàëîñü â ñòåíàõ ÐÌÑ.

Äàâàéòå îáðàòèìñÿ ê ðóêîâîäñòâàì:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
Adenoviral Conjunctivitis
Patients with adenoviral conjunctivitis should be informed of appropriate measures to reduce the risk that they may spread the infection to their other eye or to other people.[B:III] There is no effective treatment for adenovirus infection; however, artificial tears, topical antihistamines, or cold compresses may be used to mitigate symptoms.
Topical steroids are helpful to reduce scarring in severe cases of adenoviral keratoconjunctivitis with marked chemosis or lid swelling, epithelial sloughing, or membranous conjunctivitis. In an animal model of adenoviral conjunctivitis, administration of topical corticosteroid lead to prolonged viral shedding. Patients who use topical corticosteroid should be instructed to maintain precautions against the spread of the virus for 2 additional weeks after symptoms resolve.[A:III] For patients with membranous conjunctivitis, debridement of the membrane may enhance the efficacy of corticosteroid therapy and improve comfort.

Patients with severe disease who have corneal epithelial ulceration or membranous conjunctivitis should be re-evaluated within 1 week.[A:III] The follow-up visit should include an interval history, measurement of visual acuity, and slit-lamp biomicroscopy.[A:III]
Other patients should be instructed to return for follow-up if they continue to experience symptoms of red eye, pain, or decreased vision after 2 to 3 weeks.[A:III] This follow-up visit should include an interval history, measurement of visual acuity, and slit-lamp biomicroscopy.[A:III]
Patients treated with topical corticosteroids for irritation or visual symptoms due to subepithelial infiltrates or late onset epithelial granularity should have the dosage slowly tapered to the minimum effective dose.[A:III]

Corticosteroids with poor ocular penetration, such as fluorometholone, or site specific steroids, such as rimexolone, may be less likely to result in elevated intraocular pressure or cataract formation. Follow-up examination should occur every 4 to 8 weeks, and visits should include an interval history, measurement of visual acuity and intraocular pressure, and slit-lamp biomicroscopy.[A:III] Recurrence of subepithelial infiltrates has been reported in patients with a history of adenoviral infection who have undergone photorefractive keratectomy or laser in situ keratomileusis.51,52
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Çäåñü ìîæíî íàéòè ðóêîâîäñòâà ïî ìíîãèì íîçîëîãèÿì ãëàçíûõ áîëåçíåé.

Ï.Ñ. Ñîððè, ïðèâåë îòäåëüíûå ñòàòüè íà àíãëèéñêîì, áåç ïåðåâîäà, òàê êàê èäåò îáñóæäåíèå âðà÷åáíîãî àñïåêòà, íå äëÿ ïàöèåíòà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #14  
Ñòàðûé 29.09.2008, 23:30
Darina38 Darina38 âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 27.11.2007
Ãîðîä: Tashkent
Ñîîáùåíèé: 3,486
Ïîáëàãîäàðèëè 1,017 ðàç(à) çà 984 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
Darina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íî âñå-òàêè àíòèãèñòàìèíû íå èñêëþ÷àþòñÿ?
Ðå÷ü íå èäåò î íåýòè÷íîñòè, ìû íå ãîâîðèì î êàêèõ-òî íîâûõ íåèññëåäîâàííûõ íà ëþäÿõ ïðåïàðàòàõ. Ðå÷ü èäåò î òîì, ÷òî ôèç. ðàñòâîð íå ñàìîå ëó÷øåå ñðåäñòâî äëÿ ëå÷åíèÿ òÿæåëûõ àäåíîâèðóñíûõ êåðàòîêîíúþíêòèâèòîâ.
Ñ óâàæåíèåì, Äàðèíà.
Îòâåòèòü ñ öèòèðîâàíèåì
  #15  
Ñòàðûé 29.09.2008, 23:33
Darina38 Darina38 âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 27.11.2007
Ãîðîä: Tashkent
Ñîîáùåíèé: 3,486
Ïîáëàãîäàðèëè 1,017 ðàç(à) çà 984 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
Darina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDarina38 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé êîëëåãà. Ñïàñèáî çà ññûëêè. Ñ ÂÌJ ÿ çíàêîìà, à âîò ïîñëåäíèå î÷åíü èíòåðåñíû. Ñ óâàæåíèåì, Äàðèíà.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 01:09.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.